Statement of Changes in Beneficial Ownership (4)
06 December 2022 - 08:37AM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Skorpios Trust |
2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc.
[
AKRO
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) Former 10% owner |
(Last)
(First)
(Middle)
195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/1/2022 |
(Street)
LIMASSOL, G4 3030
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/1/2022 | | S(1) | | 1636000 | D | $43.50 | 3271829 | I | See Footnote (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Skorpios Trust 195 ARCH. MAKARIOS III AVE. NEOCLEOUS HOUSE LIMASSOL, G4 3030 |
|
|
| Former 10% owner |
Blue Horizon Enterprise Ltd 3076 SIR FRANCIS DRAKE'S HIGHWAY ROAD TOWN TORTOLA, D8 |
|
|
| Former 10% owner |
Ezbon International Ltd 3076 SIR FRANCIS DRAKE'S HIGHWAY ROAD TOWN TORTOLA, D8 |
|
|
| Former 10% owner |
Montrago Trustees Ltd 195 ARCH. MAKARIOS III AVE NEOCLEOUS HOUSE LIMASSOL, G4 3030 |
|
|
| Former 10% owner |
Signatures
|
/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Skorpios Trust | | 12/5/2022 |
**Signature of Reporting Person | Date |
/s/ Anna Maria Pavlou, Authorized Signatory on behalf of Blue Horizon Enterprise Ltd. | | 12/5/2022 |
**Signature of Reporting Person | Date |
/s/ Anna Maria Pavlou, Authorized Signatory on behalf of Ezbon International Limited | | 12/5/2022 |
**Signature of Reporting Person | Date |
/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Montrago Trustees Limited | | 12/5/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2023 to Mar 2024